Grünenthal is a science-based, fully-integrated pharmaceutical company headquartered in Aachen, Germany. We have affiliates in 29 countries across Europe, Latin America and the US. We employ around 4,500 people and our products are available in around 100 countries. Everything we do is focused on driving progress towards our vision of a world free of pain.
Pain represents a huge burden for people and society and the unmet medical need remains high. Addressing the unmet medical need in the treatment of all types of pain and finding and developing new treatment options to try to break the cycle is what drives our strategy. As a global leader with a unique position in pain research and management, we want to create a positive impact for society. It is due to this potential to improve the lives of patients in real need that we are committed to delivering on our vision of a world free of pain.
in € million
|Cost of sales||-419||-413|
|Marketing, Sales & Medical costs||-439||-384|
|Core Research & Development costs||-184||-137|
|Depreciation Fixed Assets||207||191|
|Earnings before taxes (EBT)||27||63|
1 Management view. Profit and loss statements (P&L) can be displayed in Accounting and Management view. Both P&Ls include the same information, but are designed to serve different needs. The Accounting P&L is used for reporting according to German Commercial Code (HGB) while the Management P&L is used for internal steering and tracking. Both views are similar for Revenue, Cost of sales and thus gross profit. But they differ in terms of the recognition of depreciation on acquired product rights and medical affairs costs. Depreciation of acquired products rights are recognized in Management view as part of “other costs” whereas Accounting view shows it as part of “selling expenses”. Medical commercial R&D costs comprise post approval product costs, e.g. for the maintenance of registration, for clinical studies for phase IIIb/IV and the support of investigator initiated studies as well as structural costs. These costs are part of “Marketing, Sales & Medical costs” in Management view whereas shown as “Research & Development costs” in Accounting view.
Being a responsible business and leader in ESG in our industry
Conducting business responsibly is a central element of our strategy and culture. We aspire to create a positive impact for society – with and beyond our core business. At all times, everything we do is guided by integrity, transparency and the highest ethical standards. This is recognized by our external ESG rating where we are in the top 5% among our peers in the pharmaceutical subindustry.
Society and the Environment
Caring for the world around us is a big part of who we are. That is why we support projects that have a positive impact on people and communities, from palliative care and charity activities through to protecting the environment.
Educated Access to Pain Management
Compliance, Ethics and Transparency
Our R&D pipeline